BioNTech SE Operating Income

BioNTech SE (BNTX) currently reports a operating income of $-1.7B as of June 2026. That compares with $-880M in the prior-year period — down 94.3% year over year. Use the charts on this page to explore BioNTech SE's operating income history and peer comparisons.

BioNTech SE's operating income decreased from $-880M to $-1.7B — a 94.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

BioNTech SE reported $-1.7B in operating income as of June 2026. That compares with $-880M in the prior-year period — down 94.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-1.7B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for BioNTech SE, and consider following BNTX for alerts when major investors trade the stock.

BioNTech SE is classified in the Healthcare sector. On operating income, it currently shows $-1.7B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BNTX with unrelated industries.